The insider sales are small in magnitude and by a venture capital investor, not management. This is likely a routine portfolio reduction and does not warrant a bearish read-through. Monitor for any C-suite selling or a material increase in sales volume, which would be a stronger signal. The stock's 86% analyst bullish consensus and recent strong institutional accumulation (7 funds doubling positions) provide a counterweight.
Price Chart
Executive Summary
Two MPM BioVentures funds, each a 10% owner of Entrada Therapeutics, sold a combined ~$400K in open-market sales over three days (Aug 24-26). The total value is 0.13% of the $297M market cap, falling in the modest proportionality band. No C-suite insiders participated, and the sales are likely part of a routine portfolio reduction by a venture capital investor, not a signal of operational deterioration. The cluster is a sell, but the dollar amount is small relative to company size and lacks executive participation, limiting its informational value.
Key Financial Metrics
Key Facts
- Two MPM BioVentures funds (10% owners) sold a combined ~$400K in open-market sales over three days.
- Total sales represent ~0.13% of TRDA's $297M market cap.
- No C-suite executives (CEO, CFO, etc.) participated in the sales.
- Sales occurred at prices between $7.06 and $7.54 per share.
- The selling is by a venture capital investor, not company management.
Financial Impact
Total insider sales of approximately $400,000, representing 0.13% of market capitalization.
Risk Factors
- Venture capital selling could continue if the funds are reducing their position over time.
- The stock has a history of high volatility (prior T+20 moves of -50% and +56% in recent months).
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 SEC document filed with EDGAR.
| Document | Accession Number |
|---|---|
| CLUSTER Data (Synthetic) | cluster-TRDA-1787794151315 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 9, 2026 22d ago | Insider Cluster | $6.42 $6.90 | ▼ −7.48% | ▼ −7.98% | $5.38 (+16.20%) |
Sep 3, 2026 29d ago | Insider Cluster | $7.17 $6.80 | ▼ −5.16% | ▼ −4.01% | $5.38 (−24.97%) |
Aug 31, 2026 4w ago | Insider Cluster | $7.07 $7.11 | ▲ +0.57% | ▲ +0.48% | $5.38 (−23.90%) |
Aug 31, 2026 4w ago | Insider Cluster | $7.07 $7.11 | ▲ +0.57% | ▲ +0.48% | $5.38 (−23.90%) |
Aug 31, 2026 4w ago | Insider Cluster | $7.07 $7.11 | ▲ +0.57% | ▲ +0.48% | $5.38 (−23.90%) |
Aug 27, 2026 5w ago | Insider Cluster | $7.27 $7.17 | ▼ −1.38% | ▼ −1.64% | $5.38 (−26.00%) |
Aug 10, 2026 7w ago | Insider Cluster | $7.04 $7.27 | ▲ +3.27% | ▲ +3.67% | $5.38 (−23.58%) |
Aug 5, 2026 8w ago | 8-K | $7.06 $7.67 | ▲ +8.64% | ▲ +8.29% | $5.38 (−23.80%) |
Aug 3, 2026 8w ago | Insider Cluster | $7.24 $7.04 | ▼ −2.76% | ▼ −2.66% | $5.38 (−25.69%) |
Jul 30, 2026 9w ago | 144 | $6.79 $6.87 | ▼ −1.18% | ▲ +2.33% | $5.38 (+20.77%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access